Unlocking the Potential of B3GNT8: A Promising Drug Target and Biomarker

Target Name: B3GNT8

NCBI ID: G374907

B3GNT8

Unlocking the Potential of B3GNT8: A Promising Drug Target and Biomarker

Introduction

Beta1,3-N-acetylglucosaminyltransferase 8 (B3GNT8) is a protein that plays a crucial role in the biosynthesis of N-acetylglucosamine (NAG), a key regulator of various cellular processes. NAG is widely expressed in tissues and functions as a chaperone, participating in a variety of cellular processes, including cell signaling, cytoskeletal organization, and neurotransmission. B3GNT8 is an enzyme that catalyzes the transfer of the acetyl group from N-acetylglucosamine (NAG) to the alpha-glucosaminyl group on the 尾-endopeptide of NAG . This enzyme is highly conserved across various species, and its function has been extensively studied. In this article, we will explore the potential of B3GNT8 as a drug target and biomarker.

Beta1,3-N-acetylglucosaminyltransferase 8 (B3GNT8)

B3GNT8 is a 23-kDa protein that is expressed in various tissues, including brain, heart, liver, and kidney. It is a member of the glycosaminyltransferase family 8, which includes enzymes involved in the biosynthesis of NAG and other carbohydrates ( 2). B3GNT8 is characterized by its unique catalytic mechanism, where it uses a nucleotide-activated irreversible non-binding coenzyme A to promote the reaction.

Functional characterization of B3GNT8

B3GNT8 is widely expressed in various tissues and has been shown to participate in the biosynthesis of NAG in various cell types. It is involved in the formation of NAG from the starting material, N-acetylglucosamine (NAG), which is a key regulator of various cellular processes, including cell signaling, cytoskeletal organization, and neurotransmission.

Recent studies have demonstrated the potential of B3GNT8 as a drug target. The ability of B3GNT8 to catalyze the transfer of the acetyl group from NAG to the alpha-glucosaminyl group on the 尾-endopeptide of NAG has led to the idea of 鈥嬧?媢sing B3GNT8 as a target for small molecules that can modulate its activity.

B3GNT8 has also been identified as a potential biomarker for various diseases, including cancer. The biosynthesis of NAG is a critical step in the regulation of cellular processes, and alterations in NAG levels have been implicated in the development and progression of many diseases , including cancer. Therefore, the inhibition of B3GNT8 activity could be a promising strategy for cancer treatment.

Theoretical models of B3GNT8

The structure of B3GNT8 has been determined through a combination of biochemical, genetic, and computational methods. The protein has a unique catalytic mechanism, where it uses a nucleotide-activated irreversible non-binding coenzyme A to promote the reaction. The coenzyme A plays a crucial role in the reaction, as it provides a proton gradient that allows the nucleotide to be activated and the carbonyl group to be transferred to the alpha-glucosaminyl group.

B3GNT8 has a distinct N-terminus, which is involved in the formation of the nucleotide-activated irreversible non-binding CoA. The C-terminus of B3GNT8 is involved in the formation of a disulfide bond, which provides stability to the protein.

Expression and regulation of B3GNT8

B3GNT8 is widely expressed in various tissues and is regulated by various factors, including DNA methylation, histone modifications, and post-transl

Protein Name: UDP-GlcNAc:betaGal Beta-1,3-N-acetylglucosaminyltransferase 8

Functions: Beta-1,3-N-acetylglucosaminyltransferase that plays a role in the elongation of specific branch structures of multiantennary N-glycans. Has strong activity towards tetraantennary N-glycans and 2,6 triantennary glycans

The "B3GNT8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B3GNT8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets